Skip to content
logo MSD Oncology Clinical Trials
  • Homepage
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Gastric
    • Gynaecologic
    • Haematological
    • Head and Neck
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Oesophageal
    • Paediatric
    • Prostate
    • Solid Tumours
  • About
  • Common Questions
  • For HCPs
  • English (AU)
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Trial Drug: Olaparib

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumours.

Trial Drug: Olaparib

Study of Olaparib in Combination With Pembrolizumab in the Treatment of Homologous Recombination Repair Mutation and/or Homologous Recombination Deficiency -Positive Advanced Cancer

March 7, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable)

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer

March 7, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer

March 7, 2022

By Tyler Kalist

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast

Efficacy and Safety of Olaparib in Participants With Previously Treated, Homologous Recombination Repair Mutation or Homologous Recombination Deficiency Positive Advanced Cancer

March 7, 2022

By clique_admin

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to

logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility
  • Contact Us

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Merck Sharp & Dohme (Australia) Pty Limited. Level 1 - Building A, 26 Talavera Road, Macquarie Park, NSW 2113
AU-NON-00575 – December 2022

Accessibility

Accessibility